Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

L-serine treatment in patients with GRIN -related encephalopathy: a phase 2A, non-randomized study

Juliá-Palacios, Natalia, Olivella, Mireia, Sigatullina Bondarenko, Mariya, Ibáñez-Micó, Salvador, Muñoz-Cabello, Beatriz, Alonso-Luengo, Olga, Soto-Insuga, Víctor, García-Navas, Deyanira, Cuesta-Herraiz, Laura, Andreo-Lillo, Patricia, Aguilera-Albesa, Sergio, Hedrera-Fernández, Antonio, González Alguacil, Elena, Sánchez-Carpintero, Rocío, Martín del Valle, Fernando, Jiménez González, Erika, Cean Cabrera, Lourdes, Medina-Rivera, Ines, Perez-Ordoñez, Marta, Colomé, Roser, Lopez, Laura, Engracia Cazorla, María, Fornaguera, Montserrat, Ormazabal, Aida, Alonso-Colmenero, Itziar, Illescas, Katia Sofía, Balsells-Mejía, Sol, Mari-Vico, Rosanna, Duffo Viñas, Maria, Cappuccio, Gerarda, Terrone, Gaetano, Romano, Roberta, Manti, Filippo, Mastrangelo, Mario, Alfonsi, Chiara, de Siqueira Barros, Bruna, Nizon, Mathilde, Gjerulfsen, Cathrine Elisabeth, Muro, Valeria L, Karall, Daniela, Zeiner, Fiona, Masnada, Silvia, Peterlongo, Irene, Oyarzábal, Alfonso, Santos-Gómez, Ana, Altafaj, Xavier, García-Cazorla, Ángeles · 2024 · Brain

Abstract

GRIN-related disorders are rare developmental encephalopathies with variable manifestations and limited therapeutic options. Here, we present the first non-randomized, open-label, single-arm trial (NCT04646447) designed to evaluate the tolerability and efficacy of L-serine in children with GRIN genetic variants leading to loss-of-function. In this phase 2A trial, patients aged 2–18 years with GRIN loss-of-function pathogenic variants received L-serine for 52 weeks. Primary end points included safety and efficacy by measuring changes in the Vineland Adaptive Behavior Scales, Bayley Scales, age-appropriate Wechsler Scales, Gross Motor Function-88, Sleep Disturbance Scale for Children, Pediatric Quality of Life Inventory, Child Behavior Checklist and the Caregiver-Teacher Report Form following 12 months of treatment. Secondary outcomes included seizure frequency and intensity reduction and EEG improvement. Assessments were performed 3 months and 1 day before starting treatment and 1, 3, 6 and 12 months after beginning the supplement. Twenty-four participants were enrolled (13 males/11 females, mean age 9.8 years, SD 4.8), 23 of whom completed the study. Patients had GRIN2B, GRIN1 and GRIN2A variants (12, 6 and 5 cases, respectively). Their clinical phenotypes showed 91% had intellectual disability (61% severe), 83% had behavioural problems, 78% had movement disorders and 58% had epilepsy. Based on the Vineland Adaptive Behavior Composite standard scores, nine children were classified as mildly impaired (cut-off score > 55), whereas 14 were assigned to the clinically severe group. An improvement was detected in the Daily Living Skills domain (P = 0035) from the Vineland Scales within the mild group. Expressive (P = 0.005), Personal (P = 0.003), Community (P = 0.009), Interpersonal (P = 0.005) and Fine Motor (P = 0.031) subdomains improved for the whole cohort, although improvement was mostly found in the mild group. The Growth Scale Values in the Cognitive subdomain of the Bayley-III Scale showed a significant improvement in the severe group (P = 0.016), with a mean increase of 21.6 points. L-serine treatment was associated with significant improvement in the median Gross Motor Function-88 total score (P = 0.002) and the mean Pediatric Quality of Life total score (P = 0.00068), regardless of severity. L-serine normalized the EEG pattern in five children and the frequency of seizures in one clinically affected child. One patient discontinued treatment due to irritability and insomnia. The trial provides evidence that L-serine is a safe treatment for children with GRIN loss-of-function variants, having the potential to improve adaptive behaviour, motor function and quality of life, with a better response to the treatment in mild phenotypes.

Overview

Integrity signals

Registry

Crossref · 10.1093/brain/awae041

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 57 references

Research works printed but not linked: 1

  1. Bayley, 2005, Bayley, N. Bayley scales of infant and toddler development

Cited by

See all 36

Metadata

Authors
Juliá-Palacios, N., Olivella, M., Sigatullina Bondarenko, M., Ibáñez-Micó, S., Muñoz-Cabello, B., Alonso-Luengo, O., Soto-Insuga, V., García-Navas, D., Cuesta-Herraiz, L., Andreo-Lillo, P., Aguilera-Albesa, S., Hedrera-Fernández, A., González Alguacil, E., Sánchez-Carpintero, R., Martín del Valle, F., Jiménez González, E., Cean Cabrera, L., Medina-Rivera, I., Perez-Ordoñez, M., Colomé, R., Lopez, L., Engracia Cazorla, M., Fornaguera, M., Ormazabal, A., Alonso-Colmenero, I., Illescas, K. S., Balsells-Mejía, S., Mari-Vico, R., Duffo Viñas, M., Cappuccio, G., Terrone, G., Romano, R., Manti, F., Mastrangelo, M., Alfonsi, C., de Siqueira Barros, B., Nizon, M., Gjerulfsen, C. E., Muro, V. L., Karall, D., Zeiner, F., Masnada, S., Peterlongo, I., Oyarzábal, A., Santos-Gómez, A., Altafaj, X., & García-Cazorla, Á.
Affiliations
  • Neurometabolic Unit and Synaptic Metabolism Lab, Department of Neurology, Hospital Sant Joan de Déu—IRSJD, CIBERER and MetabERN , 08950 Barcelona , Spain
  • Universitat de Vic - Universitat Central de Catalunya (ES)
  • Pediatric Neurology Unit, Arrixaca Universitary Hospital , 30120 Murcia , Spain
  • Department of Pediatrics, Hospital Universitario Virgen del Rocío , 41013 Sevilla , Spain
  • Neurology Service, Hospital Niño Jesús , 28009 Madrid , Spain
  • Department of Pediatric Neurology, Complejo Hospitalario Universitario de Cáceres , 10003 Cáceres , Spain
  • Hospital de Manises (ES)
  • Hospital Universitari Sant Joan D'Alacant (ES)
  • Paediatric Neurology Unit, Department of Pediatrics, Hospital Universitario de Navarra , 31008, Pamplona , Spain
  • Hospital Universitario Central de Asturias (ES)
  • Pediatric Neurology Unit, Clínica Universidad de Navarra , 31080, Pamplona , Spain
  • Department of Pediatrics, Hospital Universitario Severo Ochoa , 28911 Leganés, Madrid , Spain
  • Department of Pediatrics, Hospital Rey Juan Carlos , 28933 Móstoles, Madrid, Spain
  • Child and Adolescent Mental Health Area, Psychiatry and Psychology, Hospital Sant Joan de Déu, 08950 Barcelona , Spain
  • Institut de Recerca Sant Joan de Déu (ES)
  • Department of Rehabilitation, Institut de Recerca Sant Joan de Déu , 08950 Barcelona , Spain
  • Department of Clinical Biochemistry, Hospital Sant Joan de Déu , 08950 Barcelona , Spain
  • Hospital Sant Joan de Déu Barcelona (ES)
  • Telethon Institute Of Genetics And Medicine (IT)
  • University of Naples Federico II (IT)
  • Sapienza University of Rome (IT)
  • Policlinico Umberto I (IT)
  • Núcleo de Estudos da Saúde do Adolescente, Programa de Pós-Graduação em Ciências Médicas, Universidade do Estado do Rio de Janeiro, Faculdade de Ciência Médicas , 56066 Rio de Janeiro, RJ , Brazil
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Department of Epilepsy Genetics and Personalized Treatment, The Danish Epilepsy Center , 4293 Dianalund , Denmark
  • Hospital Británico de Buenos Aires (AR)
  • Innsbruck Medical University (AT)
  • Ospedale dei Bambini Vittore Buzzi (IT)
  • Department of Biomedicine, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona , 08036 Barcelona , Spain
  • Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
Venue
Brain
Published
2024-02-21
Volume
147
Issue
5
Pages
1653-1666
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4391996859
Cited by
36
References
57
Citations by year
2026: 14 · 2025: 16 · 2024: 6
FWCI
9.52
Type
journal article
Language
en
Open access
closed
Locations
  • Brain (publishedVersion)
  • PubMed (publishedVersion)
  • RIUVic (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders
  • Nutricia Metabolics Research Fund (FI21/00073)
  • Instituto de Salud Carlos III
  • Fondo Europeo de desarrollo regional
  • European Regional Development Fund (PI19/00348, PI22/00515)
  • Fundación Tatiana Pérez de Guzmán El Bueno
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
NR2B subunit, GRIN1, GRIN2A, loss-of-function mutations, intellectual disability, developmental encephalopathy, seizure reduction, adaptive behavior, motor function, sleep disorders, quality of life, children, dietary supplementation, tolerability, epilepsy, movement disorders, behavioral problems, EEG improvement, Vineland Adaptive Behavior Scales
MeSH terms
Adolescent, Brain Diseases, Child, Child, Preschool, Female, Humans, Male, Quality of Life, Serine, Receptors, N-Methyl-D-Aspartate, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: L-serine treatment in patients with GRIN -related encephalopathy: a phase 2A, non-randomized study. https://app.cochat.ai/papers/10.1093/brain/awae041
The paper
Juliá-Palacios, N., Olivella, M., Sigatullina Bondarenko, M., Ibáñez-Micó, S., Muñoz-Cabello, B., Alonso-Luengo, O., Soto-Insuga, V., García-Navas, D., Cuesta-Herraiz, L., Andreo-Lillo, P., Aguilera-Albesa, S., Hedrera-Fernández, A., González Alguacil, E., Sánchez-Carpintero, R., Martín del Valle, F., Jiménez González, E., Cean Cabrera, L., Medina-Rivera, I., Perez-Ordoñez, M., . . . García-Cazorla, Á. (2024). L-serine treatment in patients with GRIN -related encephalopathy: a phase 2A, non-randomized study. Brain. https://doi.org/10.1093/brain/awae041

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.